ProteoGenix was founded in 2002 with the goal of creating new diagnostic tools that provide improved laboratory testing results to the maternal/fetal/neonatal health care community. Better information will facilitate more effective diagnosis and management of critical conditions associated with pregnancy such as intraamniotic infection, neonatal sepsis, preterm birth and preeclampsia.

ProteoGenix was the first to identify and characterize a fundamental map of more than 800 proteins in the key biologic fluids unique to pregnancy and demonstrate how this landscape is altered in important pregnancy-related disorders. Furthermore, ProteoGenix utilizes cutting edge nucleic acid-based molecular technologies, proteomic, and proprietary bioinformatic technologies to identify specific biomarkers associated with common maternal and fetal disorders, many of which are difficult to diagnose.

This groundbreaking work defining the “Proteome of Pregnancy” has been the topic of numerous peer-reviewed publications and has received significant scientific attention, including being selected as “Best Clinical Study” at the 2007 Annual Meeting of the Society for Maternal-Fetal Medicine.

ProteoGenix has also developed the unique capability to utilize sophisticated nucleic acid-based molecular technologies such as Quantitative/Real-Time polymerase chain reaction (qPCR) and Pyrosequencing, specifically optimized for use in key maternal/fetal/neonatal biological fluids, to detect infectious and pathophysiological diseases. These technologies can be used as diagnostic tests themselves for detection of infection and also to aid in the selection of proteomic bio markers that specifically correlate with critical maternal/fetal/neonatal conditions.

Market research clearly indicates clinicians are relatively unsatisfied with the currently available diagnostic tools for many of the critical conditions associated with pregnancy and that significant unmet medical needs persist in this area. In addition, it is clear the limitations of currently available diagnostic tools in this area have a significant impact on overall U.S. healthcare costs.